Investigators found data from the National Notifiable Diseases Surveillance System that showed hepatitis C virus infection rates doubled among women of reproductive age between 2006 and 2014.
Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
Although hepatic vein pressure gradient measurement is an accurate method for evaluation of portal HTN, this technique is invasive and not widely available.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
Researchers analyzed data from patients with chronic hepatitis B to identify predictors of relapse in those who discontinued NAs and determined if existing rules for stopping NA therapy can be improved.
Researchers analyzed data from patients with chronic hepatitis B to identify predictors of relapse in those who discontinued NAs and determined if existing rules for stopping NA therapy can be improved.
The researchers wanted to collect data about the real-world effectiveness and safety of SOF/VEL in patients with chronic HCV infection and severe renal impairment.
The researchers’ objective was to determine the prevalence of HCV antibodies among MSM with and without HIV, as well as factors associated with HCV infection among MSM.
This study’s goal was to study the effect of fatty liver on the incidence of cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in patients with chronic hepatitis B.
In their presentation at The Liver Meeting, a team of investigators from the University of California, San Francisco sought to assess pregnancy outcomes in women with autoimmune hepatitis.
Increased utilization of HCV-positive liver allografts for LT is seen as one of the ways to counter national organ shortages, so researchers set out to better characterize the allografts that come from HCV-positive donors from specific regions.
Based on guidelines issued by the World Health Organizations in 2018, the American College of Physicians has issued best practice advice that simplifies and improves treatment of chronic hepatitis C virus.
Measuring liver stiffness should be considered after anti-viral treatment because it predicts adverse outcomes even beyond routinely available clinical predictors.
Italian investigators conducted a prospective, multicenter study to assess the safety and effectiveness of glecaprevir/pibrentasvir in chronic hepatitis C patients and their subpopulations.
A study published in the Annals of Internal Medicine found transplanting kidneys from hepatitis C virus (HCV)-positive donors to HCV-negative recipients (HCV D+/R-) may be successful with prophylactic treatment with direct-acting antivirals.
Researchers conducted a simulated economic evaluation cohort analyses to assess the cost-effectiveness of HCV screening and compared other screening programs in the United States.
